Artificial Intelligence in Mammography Screening in Norway

NARecruitingINTERVENTIONAL
Enrollment

150,000

Participants

Timeline

Start Date

November 25, 2024

Primary Completion Date

November 30, 2026

Study Completion Date

June 30, 2033

Conditions
Breast Cancer
Interventions
OTHER

AI assisted mammography screening interpretation

Screening examinations will be analyzed by the AI system (Transpara, ScreenPoint Medical, Nijmegen, The Netherlands) that assigns each examination a cancer risk score 1-10. Examinations with a score 1-7 will be single read and examinations with score 8-10 will be double read. Examinations selected by one or two readers will be discussed in a consensus meeting. Examinations with an AI score of \>9.8 will be selected for the consensus meeting by default. AI risk scores and image markings are provided to the readers only in the consensus meetings. The readers will decide whether to recall the woman for further assessment in consensus (standard procedure).

OTHER

Standard mammography screening interpretation

Screening examinations will be assessed according to standard of care: independently double read, examinations selected by one or two readers will be discussed in a consensus meeting, and the radiologists will decide whether to recall the woman for further assessment. Screening examinations will be analyzed by the AI system retrospectively but the results will not be made available to the radiologist, only used for comparison to the intervention group in results analyses.

Trial Locations (1)

Unknown

RECRUITING

Cancer Registry of Norway, Norwegian Institute of Public Health, Oslo

All Listed Sponsors
collaborator

Helse Vest

OTHER

collaborator

Helse Midt-Norge

OTHER

collaborator

Helse Nord

INDUSTRY

collaborator

Norwegian Cancer Society

OTHER

lead

Norwegian Institute of Public Health

OTHER_GOV